- life sciences/pharma sector
-
Population PK-PD
Fulfilling its Promise as a Tool to Optimise Clinical Drug Development
Event Date: 24-25 Sep 2009
Location: Thistle Marble Arch, London, UK
- key conference speakers
-
Dr Rik de Greef Group Leader-Project PK and Modelling Representatives, PK, PD and Pharmacometrics , Schering-Plough Dr Alun Bedding Director of Biostatistics, GSK Dr An Vermeulen Senior Director, Global Head Advanced Modelling and Simulation, Johnson and Johnson Dr Neil Benson Associate Research Fellow, Leader Systems, Pfizer Dr Dinesh De Alwis Senior Research Advisor, Group Leader Global PK-PD , Eli Lilly
- key conference topics
-
- Learn how to optimise the design of population PK-PD studies while integrating the use of novel methodologies
- Examine best practices in biomarker identification and qualification to facilitate translation
- Master the application of Population PK-PD modelling cross therapeutic area
- Examine hands-on physiological and mechanism-based modelling approaches for PK and PD analysis
- Analyse the different statistical approaches to best apply to your study – Bayesian or Frequentist
- key conference features
-
- Sanofi Aventis probing the challenges in pharmacologically- based modelling for paediatric studies
- Bayer Healthcare discovering ways to understand and extrapolate PK and PD data by matching physiology based and NONMEM modelling
- Schering-Plough integrating PK-PD applications in CNS drug development
- Novo Nordisk applying PK-PD within mechanistic disease models
- who should attend the conference
-
Vice Presidents, Directors and Heads from the following functions:
• Pharmacokinetics
• Pharmacodynamics
• Pharmacometrics
• Modelling and Simulation
• Pharmacology
• Translational/Experimental/Discovery Medicine
• Biomarkers
• Biostatistics
• Preclinical Development
• Clinical Development
As well as experts from the leading academic institutions from across the globe.
- the conference organisers
-
marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.
Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.
- conference speakers
-
Dr Laura Sargentini-Maier
Director, Clinical Pharmacokinetics Modelling and Simulation
UCB-Pharma
Dr Rik de Greef
Group Leader-Project PK and Modelling Representatives, PK, PD and Pharmacometrics
Schering-Plough
Dr Willi Weber
Clinical Pharmacology Advisor
Sanofi Aventis
Dr Steen Ingwersen
Director of Biomodelling
Novo Nordisk
Dr Elizabeth CM de Lange, PhD
Head of Target Site Equilibration Group
LACDR/Pharmacology, Leiden University
Dr Sandra Visser, PhD
Associate Principal Scientist, Teamleader Discovery PK-PD
Astra Zeneca
Dr Rolf Burghaus
Head of Modelling and Simulation
Bayer Healthcare
Dr Alun Bedding
Director of Biostatistics
GSK
Dr An Vermeulen
Senior Director, Global Head Advanced Modelling and Simulation
Johnson and Johnson
Dr Liesbeth Rook
Population PK-PD expert
Medicines Evaluation Board
Dr Neil Benson
Associate Research Fellow, Leader Systems
Pfizer
Dr Johan Areberg
Pharmacokineticist, Clinical Pharmacology
Lundbeck
Dr Alexander Staab
Team Leader Pharmacometrics
Boehringer Ingelheim
Dr Dinesh De Alwis
Senior Research Advisor, Group Leader Global PK-PD
Eli Lilly
Prof. Marc Lavielle
Research Director
INRIA Saclay
Dr Richard Bax
Former Vice President
Viropharma Pharmaceuticals EU
- general enquiries
-
Ola Samuelsson
11 Connaught Place
London
W2 2ET
Telephone: +44(0)20 3002 3276
Fax: +44(0)20 3002 3016
Email: olas@marcusevansuk.com
- sponsorship opportunities
-
Nisha Vyas
11 Connaught Place
LONDON
W2 2ET
Telephone: +44(0)20 3002 3171
Fax: +44 (0)20 3002 3484
Email: nishav@marcusevansuk.com
- conference quote
-
"Embrace the New Age of Model-Based Drug Development "
Integrate pharmacokinetic and pharmacodynamic principles into the drug development to make it more rational and efficient. Join leading industry and academia experts to hear how PK-PD is implemented in their organisations to eliminate flawed candidates at the beginning of the development process and decrease risk of failure at the final stage
